中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2008年
6期
628-631
,共4页
梁启廉%张英%赖振南%蔡良真%黄杰%李土华%罗海清%杨勤
樑啟廉%張英%賴振南%蔡良真%黃傑%李土華%囉海清%楊勤
량계렴%장영%뢰진남%채량진%황걸%리토화%라해청%양근
肺肿瘤放化疗法%血清可溶性Fas%酶联免疫吸附试验
肺腫瘤放化療法%血清可溶性Fas%酶聯免疫吸附試驗
폐종류방화요법%혈청가용성Fas%매련면역흡부시험
Lung neoplasms/radio-chemotherapy%Serum soluble Fas%Enzyme linked
目的 用酶联免疫吸附试验研究非小细胞肺癌患者同步放化疗对血清可溶性Fas的影响及其与预后的关系.方法 对60例患者比较治疗前、治疗后1个月血清Fas水平变化,并设正常对照组.比较治疗有效组(完全缓解+部分缓解,50例)与无效组(无变化+进展,10例)治疗前Fas水平变化.以2年生存为观察指标,观察血清Fas水平对生存时间的影响.结果 非小细胞肺癌患者治疗前血清Fas水平明显高于正常对照组(8.55±0.63)ng/L和(6.03±0.55)ng/L(t=18.63,P<0.01),治疗后1个月明显低于治疗前(7.24±0.52)ng,L和(8.55±0.63)ng,L(t=12.44,P<0.01).治疗有效组疗前血清Fus水平明显低于无效组的(8.02±0.43)ng/L和(8.97±0.42)ng/L(t=8.67,P<0.01).生存满2年者(26例)治疗前Fas水平明显低于生存不足2年者(34例)(t=645.88,P<0.05).结论 同步放化疗可降低非小细胞肺癌患者血清可溶性Fas水平,治疗前后Fas水平变化有可能成为判断非小细胞肺癌患者预后的观察指标.
目的 用酶聯免疫吸附試驗研究非小細胞肺癌患者同步放化療對血清可溶性Fas的影響及其與預後的關繫.方法 對60例患者比較治療前、治療後1箇月血清Fas水平變化,併設正常對照組.比較治療有效組(完全緩解+部分緩解,50例)與無效組(無變化+進展,10例)治療前Fas水平變化.以2年生存為觀察指標,觀察血清Fas水平對生存時間的影響.結果 非小細胞肺癌患者治療前血清Fas水平明顯高于正常對照組(8.55±0.63)ng/L和(6.03±0.55)ng/L(t=18.63,P<0.01),治療後1箇月明顯低于治療前(7.24±0.52)ng,L和(8.55±0.63)ng,L(t=12.44,P<0.01).治療有效組療前血清Fus水平明顯低于無效組的(8.02±0.43)ng/L和(8.97±0.42)ng/L(t=8.67,P<0.01).生存滿2年者(26例)治療前Fas水平明顯低于生存不足2年者(34例)(t=645.88,P<0.05).結論 同步放化療可降低非小細胞肺癌患者血清可溶性Fas水平,治療前後Fas水平變化有可能成為判斷非小細胞肺癌患者預後的觀察指標.
목적 용매련면역흡부시험연구비소세포폐암환자동보방화료대혈청가용성Fas적영향급기여예후적관계.방법 대60례환자비교치료전、치료후1개월혈청Fas수평변화,병설정상대조조.비교치료유효조(완전완해+부분완해,50례)여무효조(무변화+진전,10례)치료전Fas수평변화.이2년생존위관찰지표,관찰혈청Fas수평대생존시간적영향.결과 비소세포폐암환자치료전혈청Fas수평명현고우정상대조조(8.55±0.63)ng/L화(6.03±0.55)ng/L(t=18.63,P<0.01),치료후1개월명현저우치료전(7.24±0.52)ng,L화(8.55±0.63)ng,L(t=12.44,P<0.01).치료유효조료전혈청Fus수평명현저우무효조적(8.02±0.43)ng/L화(8.97±0.42)ng/L(t=8.67,P<0.01).생존만2년자(26례)치료전Fas수평명현저우생존불족2년자(34례)(t=645.88,P<0.05).결론 동보방화료가강저비소세포폐암환자혈청가용성Fas수평,치료전후Fas수평변화유가능성위판단비소세포폐암환자예후적관찰지표.
Objective Study on the change of serum soluble Fas (sFas) level and prognostic relation for non.small cell lung cancer (NSCLC) patients with concurrent radio-chemotherapy using enzyme linked immunosorbent assays(ELISA). Methods Sixty patients were obtained. The sFas level were compared before treatment with one month after treatment, and healthy donors were used as controls level of sFas. The sFas level of before treatment were compared treatment efficiency patients (complete remission and partial remission, 50patients) and treatment inefficiency patients(no change and progressive disease, 10 patients). The correlation was analyzed between 2-year survival NSCLC patients and their sFas level. Results The sFas level before treatment in NSCLC patients was obviously higher than healthy controls (8.55±0.63) ng/L and (6.03±0.55)ng/L; (t=18.63, P<0.01), with 1 month after treatment obviously lower than before treatment in NSCLC patients (7.24±0.52) ng/L and (8.55±0.63) ng/L; (t=12.44, P<0.01). The sFas level of before treatment was treatment efficiency patients obviously lower than treatment ineffectived patients (8.02±0.43) ng/L and, (8.97±0.42) ng/L; (t = 8.67, P < 0.01 ), with 2-year survival patients obviously(26 patients) lower than shortage 2-year survival patients (34 patients) (t = 645.88, P < 0.05). Conclusions Concurrent radio-chemotherapy can reduce sFas level in NSCLC patients, the changes of sFas level before and after treatment may previde worth prognostic for NSCLC patients.
